• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.读者回应：用于中度晚期帕金森病的AADC基因疗法的安全性：PD - 1101试验的三年结果
Neurology. 2022 Aug 9;99(6):258-259. doi: 10.1212/WNL.0000000000201002.
2
Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.读者回应：AADC基因疗法治疗中度晚期帕金森病的安全性：PD - 1101试验的三年结果
Neurology. 2022 Aug 9;99(6):260. doi: 10.1212/WNL.0000000000201004.
3
Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.作者回复：AADC基因疗法治疗中度晚期帕金森病的安全性：PD - 1101试验的三年结果
Neurology. 2022 Aug 9;99(6):260-261. doi: 10.1212/WNL.0000000000201005.
4
Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.作者回复：AADC基因疗法治疗中度晚期帕金森病的安全性：PD - 1101试验的三年结果
Neurology. 2022 Aug 9;99(6):259. doi: 10.1212/WNL.0000000000201003.
5
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.壳核芳香族氨基酸脱羧酶基因治疗帕金森病的安全性和耐受性
Neurology. 2009 Nov 17;73(20):1662-9. doi: 10.1212/WNL.0b013e3181c29356. Epub 2009 Oct 14.
6
Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.帕金森病患者尾状核和壳核中芳香族氨基酸脱羧酶（AADC）活性的耗竭；对正在进行的腺相关病毒2型-AADC基因治疗试验的启示。
PLoS One. 2017 Feb 6;12(2):e0169965. doi: 10.1371/journal.pone.0169965. eCollection 2017.
7
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease.帕金森病hAADC基因治疗I期安全性试验结果。
Neurology. 2008 May 20;70(21):1980-3. doi: 10.1212/01.wnl.0000312381.29287.ff. Epub 2008 Apr 9.
8
Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.AADC 基因治疗中度晚期帕金森病的安全性：PD-1101 试验的 3 年结果。
Neurology. 2022 Jan 4;98(1):e40-e50. doi: 10.1212/WNL.0000000000012952. Epub 2021 Oct 14.
9
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease.芳香族 L-氨基酸脱羧酶基因治疗帕金森病的 I 期研究。
Mol Ther. 2010 Sep;18(9):1731-5. doi: 10.1038/mt.2010.135. Epub 2010 Jul 6.
10
Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease.芳香族 L-氨基酸脱羧酶基因治疗增强帕金森病对左旋多巴的反应。
Mov Disord. 2020 May;35(5):851-858. doi: 10.1002/mds.27993. Epub 2020 Mar 9.

引用本文的文献

1
Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease.克服帕金森病运动和非运动症状的治疗模块新视角。
AIMS Neurosci. 2024 Sep 6;11(3):312-340. doi: 10.3934/Neuroscience.2024020. eCollection 2024.

本文引用的文献

1
Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.AADC 基因治疗中度晚期帕金森病的安全性：PD-1101 试验的 3 年结果。
Neurology. 2022 Jan 4;98(1):e40-e50. doi: 10.1212/WNL.0000000000012952. Epub 2021 Oct 14.
2
Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice.未受调控的胞质多巴胺会导致与小鼠氧化应激相关的神经退行性变。
J Neurosci. 2008 Jan 9;28(2):425-33. doi: 10.1523/JNEUROSCI.3602-07.2008.
3
Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.在帕金森病大鼠中，囊泡单胺转运体-2和芳香族L-氨基酸脱羧酶可增强左旋多巴给药后的多巴胺递送。
J Neurosci. 1999 Apr 15;19(8):3266-74. doi: 10.1523/JNEUROSCI.19-08-03266.1999.
4
The role of glutathione in dopaminergic neuronal survival.谷胱甘肽在多巴胺能神经元存活中的作用。
J Neurochem. 1997 Nov;69(5):1850-8. doi: 10.1046/j.1471-4159.1997.69051850.x.
5
Regulation of dopamine production by genetically modified primary fibroblasts.转基因原代成纤维细胞对多巴胺生成的调控
J Neurosci. 1993 Dec;13(12):5203-11. doi: 10.1523/JNEUROSCI.13-12-05203.1993.

Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.

作者信息

Kang Un Jung, Nakamura Ken, Zhuang Xiaoxi

机构信息

(New York).

(San Francisco).

出版信息

Neurology. 2022 Aug 9;99(6):258-259. doi: 10.1212/WNL.0000000000201002.

DOI:10.1212/WNL.0000000000201002
PMID:35940895
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10499428/
Abstract
摘要